Shares of Bio-Techne Corp. advanced 7.39% to $50.91 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.38% to 7,337.11 and Dow ...
1d
Why Bio-Techne (TECH) Is Up 5.9% After Profits Rose Despite Slightly Lower Sales – And What's Next
Bio-Techne Corporation has released its third-quarter fiscal 2026 results, reporting sales of US$311.42 million and net income of US$51.05 million, alongside higher basic and diluted earnings per ...
May 6 (Reuters) - Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.
The company's 10-K for fiscal year 2024 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during ...
For more information on Bio-Techne and its brands, please visit or follow the company on social media at LinkedIn , X , or YouTube . Forward Looking Statements: Our press releases may contain forward ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...
Bio-Techne Corporation ( TECH) Q3 2026 Earnings Call May 6, 2026 9:00 AM EDT Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter and Fiscal Year 2026. [Operator ...
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results